Actively Recruiting
TLN-372 in Advanced KRAS Mutant Solid Tumors
Led by Treeline Biosciences, Inc. · Updated on 2026-04-21
240
Participants Needed
11
Research Sites
339 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
CONDITIONS
Official Title
TLN-372 in Advanced KRAS Mutant Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients must have measurable disease at study entry.
- Patients must have locally advanced or metastatic KRAS mutant solid tumors.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function.
You will not qualify if you...
- Patients must not have active brain metastases.
- Patients must not have current or past history of central nervous system (CNS) involvement.
- Patients must not have major surgery or severe trauma within 4 weeks prior to the start of the study.
- Patients must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places patients at unacceptable risk of participating in this study.
- Patients must not have clinically significant cardiovascular disease.
- Pregnant or lactating.
- Conditions that could affect drug absorption.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
2
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215-5450
Actively Recruiting
3
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
4
Washington University Medical Campus
St Louis, Missouri, United States, 63108
Actively Recruiting
5
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10021-3402
Actively Recruiting
6
Sarah Cannon Research Institute
Nashville, Tennessee, United States, 37203
Actively Recruiting
7
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia
Actively Recruiting
8
Linear Clinical Research
Perth, Western Australia, Australia, 6009
Actively Recruiting
9
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 1X6
Actively Recruiting
10
Hospital Universitary Vall d'Hebron
Barcelona, Spain, 08035
Actively Recruiting
11
START Madrid_Hospital Universitario HM Sanchinarro_CIOCC
Madrid, Spain, 28050
Actively Recruiting
Research Team
T
Treeline Clinical Operations
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here